A preclinical animal model trial found that simultaneous targeting of PD-1 and GITR synergistically enhanced CD8+ T cell memory and antitumor function, and these encouraging results may provide a new direction for the clinical treatment of HNSCC (Wang et al., 2018). The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.